Eagle Pharmaceuticals (EGRX) Misses Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Eagle Pharmaceuticals (EGRX) Reports Tough 3Q Results; Piper Jaffray Cuts Price target to $97
November 12, 2015 9:29 AM ESTPiper Jaffray reiterates an Overweight rating on Eagle Pharmaceuticals (NASDAQ: EGRX), and cut the price target to $97.00 (from $120.00), following the company's 3Q earnings report. Eagle reported EPS of ($0.65) on revenues of $6M, missing consensus on both. Analyst David Amsellem continues to believe there is optionality associated with Ryanodex in exertional heat stroke (EHS),... More
